drugset / Trial / NCT02590510

Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis

NCT02590510

Phase 4 Unknown 50 enrolled Hui Bu
RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to compare the effect of 10 mg and 15 mg methotrexate in the treatment of meningeal carcinomatosis.

Timeline

Start
2015-10
Primary completion
2017-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 10 mg Intrathecal
Subject Methotrexate Small molecule 15 mg Intrathecal

Indications